Nuformix (NFX) is a pharmaceutical development company, targeting unmet clinical needs in fibrosis and oncology via drug repurposing: it uses its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus bringing new and attractive commercial opportunities. NFX's early-stage pipeline has potential for significant value and early licensing opportunities. NFX's business model is to take its assets to key value creation inflection points before partnering or licensing.
|15 July 2021
||Finals - Progressing NXP002 towards clinical trials
|10 March 2021